Brandsaeter Bjørn, Broomé Ulrika, Isoniemi Helena, Friman Styrbjörn, Hansen Bent, Schrumpf Erik, Oksanen Antti, Ericzon Bo-Göran, Höckerstedt Krister, Mäkisalo Heikki, Olsson Rolf, Olausson Michael, Kirkegaard Preben, Bjøro Kristian
Department of Medicine, Rikshospitalet, Oslo, Norway.
Liver Transpl. 2003 Sep;9(9):961-9. doi: 10.1053/jlts.2003.50169.
Primary sclerosing cholangitis (PSC) is a common indication for liver transplantation, but evaluation of patients and timing of liver transplantation remain as major problems. Data from PSC and control patients listed for liver transplantation from 1990 through 2000 in the Nordic countries were recorded prospectively. Outcomes from the waiting list and after transplantation have been recorded for both groups. For PSC patients, regression analyses have been performed to analyze predictors of outcome. A total of 255 PSC and 610 control patients were accepted on the liver transplantation waiting list from 1990 to 2000. In the PSC group, 223 patients (87%) received a first liver allograft, and 32 patients (13%) died without transplantation. The corresponding figures for the control group were 89% and 10%. For PSC patients, the 5- and 10-year survival from the time of acceptance was 68% and 58%, respectively. A higher Model for End-Stage Liver Disease score and a shorter duration of PSC predicted death on the waiting list for PSC patients. PSC is a frequent indication for liver transplantation. In our material, serum bilirubin or Model for End-Stage Liver Disease score and PSC duration are predictors of outcome including survival of the waiting list.
原发性硬化性胆管炎(PSC)是肝移植的常见适应症,但患者评估和肝移植时机仍然是主要问题。前瞻性记录了1990年至2000年北欧国家列入肝移植名单的PSC患者和对照患者的数据。两组均记录了等待名单上和移植后的结果。对于PSC患者,进行了回归分析以分析结果的预测因素。1990年至2000年,共有255例PSC患者和610例对照患者被列入肝移植等待名单。在PSC组中,223例患者(87%)接受了首次肝移植,32例患者(13%)未移植死亡。对照组的相应数字分别为89%和10%。对于PSC患者,从被列入名单时起的5年和10年生存率分别为68%和58%。较高的终末期肝病模型评分和较短的PSC病程可预测PSC患者在等待名单上的死亡。PSC是肝移植的常见适应症。在我们的资料中,血清胆红素或终末期肝病模型评分以及PSC病程是包括等待名单上的生存情况在内的结果的预测因素。